Anti-LRIT3 monoclonal antibody
Pre-made anti-LRIT3 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to LRIT3/LRIT3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP1110-Ab-1/ GM-Tg-hg-IP1110-Ab-2 | Anti-Human LRIT3 monoclonal antibody | Human |
GM-Tg-rg-IP1110-Ab-1/ GM-Tg-rg-IP1110-Ab-2 | Anti-Rat LRIT3 monoclonal antibody | Rat |
GM-Tg-mg-IP1110-Ab-1/ GM-Tg-mg-IP1110-Ab-2 | Anti-Mouse LRIT3 monoclonal antibody | Mouse |
GM-Tg-cynog-IP1110-Ab-1/ GM-Tg-cynog-IP1110-Ab-2 | Anti-Cynomolgus/ Rhesus macaque LRIT3 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP1110-Ab-1/ GM-Tg-felg-IP1110-Ab-2 | Anti-Feline LRIT3 monoclonal antibody | Feline |
GM-Tg-cang-IP1110-Ab-1/ GM-Tg-cang-IP1110-Ab-2 | Anti-Canine LRIT3 monoclonal antibody | Canine |
GM-Tg-bovg-IP1110-Ab-1/ GM-Tg-bovg-IP1110-Ab-2 | Anti-Bovine LRIT3 monoclonal antibody | Bovine |
GM-Tg-equg-IP1110-Ab-1/ GM-Tg-equg-IP1110-Ab-2 | Anti-Equine LRIT3 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP1110-Ab-1/ GM-Tg-hg-IP1110-Ab-2; GM-Tg-rg-IP1110-Ab-1/ GM-Tg-rg-IP1110-Ab-2; GM-Tg-mg-IP1110-Ab-1/ GM-Tg-mg-IP1110-Ab-2; GM-Tg-cynog-IP1110-Ab-1/ GM-Tg-cynog-IP1110-Ab-2; GM-Tg-felg-IP1110-Ab-1/ GM-Tg-felg-IP1110-Ab-2; GM-Tg-cang-IP1110-Ab-1/ GM-Tg-cang-IP1110-Ab-2; GM-Tg-bovg-IP1110-Ab-1/ GM-Tg-bovg-IP1110-Ab-2; GM-Tg-equg-IP1110-Ab-1/ GM-Tg-equg-IP1110-Ab-2 |
Products Name | Anti-LRIT3 monoclonal antibody |
Format | mab |
Target Name | LRIT3 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | Cytokine antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-LRIT3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP1110-Ag-1 | Recombinant multi-species LRIT3/ CSNB1F/ FIGLER4 protein |
Cytokine | GM-Tg-g-IP1110-Ag-1 | leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 (LRIT3) protein |
Target information
Target ID | GM-IP1110 |
Target Name | LRIT3 |
Gene ID | 345193,242235,502596,698360,610534,101083079,511618,100072841 |
Gene Symbol and Synonyms | CSNB1F,FIGLER4,Gm421,LRIT3,RGD1559637 |
Uniprot Accession | Q3SXY7 |
Uniprot Entry Name | LRIT3_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | Cytokine Target |
Disease | N/A |
Gene Ensembl | ENSG00000183423 |
Target Classification | N/A |
The target: LRIT3, gene name: LRIT3, also named as CSNB1F, FIGLER4. This gene encodes a protein that has a fibronectin type III domain and a C-terminal transmembrane domain, as well as a leucine-rich repeat domain and immunoglobulin-like domain near the N-terminus. The encoded protein may regulate fibroblast growth factor receptors and affect the modification of these receptors, which are glycosylated differently in the Golgi and endoplasmic reticulum. Mutations in this gene are associated with congenital stationary night blindness, type 1F. [provided by RefSeq, May 2013].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.